Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
Hyperthermia, with no signs of any underlying infection, may occur in the course of neuroleptic malignant syndrome, fatal catatonia, heat stroke, or malignant hyperthermia. We describe hyperthermia as a complication after discontinuance of antiparkinsonian treatment with levodopa/carbidopa and bromocriptine. Impaired nigrostriatal, hypothalamic, and mesolimbic dopaminergic functions could be involved in pathogenesis.
D001833:Body Temperature Regulation; D001971:Bromocriptine / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008305:Malignant Hyperthermia / Q000175:diagnosis; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000378:metabolism*
D004338:Drug Combinations; D011954:Receptors, Dopamine; C009265:carbidopa, levodopa drug combination; D001971:Bromocriptine; D007980:Levodopa; D002230:Carbidopa